How I treat diffuse large B-cell lymphoma.

Melchardt, T; Egle, A; Greil, R

Melchardt, T; Egle, A; Greil, R.

Afiliação

Melchardt T; IIIrd Medical Department at the Paracelsus Medical University Salzburg, Cancer Center, Salzburg; Salzburg Cancer Research Institute, Salzburg; Austrian Group for Medical Tumor Therapy (AGMT), Salzburg; Cancer Cluster, Salzburg, Austria.
Egle A; IIIrd Medical Department at the Paracelsus Medical University Salzburg, Cancer Center, Salzburg; Salzburg Cancer Research Institute, Salzburg; Austrian Group for Medical Tumor Therapy (AGMT), Salzburg; Cancer Cluster, Salzburg, Austria.
Greil R; IIIrd Medical Department at the Paracelsus Medical University Salzburg, Cancer Center, Salzburg; Salzburg Cancer Research Institute, Salzburg; Austrian Group for Medical Tumor Therapy (AGMT), Salzburg; Cancer Cluster, Salzburg, Austria. Electronic address: r.greil@salk.at.

ESMO Open ; 8(1): 100750, 2023 02.

Article em En | MEDLINE | ID: mdl-36634531

Assuntos

Protocolos de Quimioterapia Combinada Antineoplásica; Linfoma Difuso de Grandes Células B; Humanos; Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico; Linfoma Difuso de Grandes Células B/tratamento farmacológico; Prognóstico; Imunoterapia

Palavras-chave

CAR-T cells; diffuse large B-cell lymphoma; interim PET; polatuzumab vedotin

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma Difuso de Grandes Células B Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: ESMO Open Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Áustria

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google